Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-26 @ 3:58 AM
Study NCT ID:
NCT04984018
Status:
UNKNOWN
Last Update Posted:
2021-07-30
First Post:
2021-07-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-07-20
First Submit QC Date:
None
Study First Post Date:
2021-07-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-29
Last Update Post Date:
2021-07-30
Last Update Post Date Type:
ACTUAL